drugset / Trial / NCT01047540
Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The aim of the study is to find out whether AIC316 is safe and efficacious for the prevention of reactivation of genital herpes
Timeline
- Start
- 2010-03
- Primary completion
- 2010-12
- Completion
- 2011-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pritelivir | Small molecule | 5 mg | Oral |
| Subject | Pritelivir | Small molecule | 25 mg | Oral |
| Subject | Pritelivir | Small molecule | 75 mg | Oral |
| Subject | Pritelivir | Small molecule | 400 mg | Oral |